Evaluation of the Utility of an Environmental Exposure Chamber (EEC) for Assessing Efficacy of Specific Immunotherapy (SIT) in Pivotal Clinical Trials
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis; Grass pollen hypersensitivity
- Focus Therapeutic Use
- Sponsors Allergopharma
- 16 Jan 2018 Status changed from completed to discontinued.
- 15 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record
- 26 Nov 2014 New trial record